This is a type of brain tumor that starts in cells called oligodendrocytes. It's usually slow-growing. It can happen at any age, but is more common in adults. Doctors often find it during tests for other reasons, like headaches or seizures. It's treated with surgery, sometimes followed by radiation or chemotherapy depending on the type and how much it has spread.
Every report comes from a Lived member, sent anonymously.
Have you had Craniotomy for Oligodendroglioma?
An oligodendroglioma is a tumor that starts in the brain, or less often the spinal cord, rather than spreading there from elsewhere in the body. It belongs to the family of tumors called gliomas, and it gets its name because its cells resemble oligodendrocytes, the cells that support and insulate nerve fibers. It most often grows in the brain's white matter (the bundles of insulated nerve fibers that connect brain regions) and its outer layer, the cortex. The most common first sign is a seizure: around 60 percent of people have one before the tumor is found. Others notice headaches, changes in thinking or memory, weakness, numbness or trouble with balance, depending on which part of the brain is affected. Oligodendrogliomas come in two grades. Grade 2 tumors grow slowly, often for years before causing symptoms, but they spread into the surrounding brain rather than staying neatly contained, which is why surgery alone rarely removes every cell. Grade 3 tumors, previously called anaplastic oligodendrogliomas, grow faster and behave more aggressively. Oligodendrogliomas rarely spread outside the brain and spinal cord.
In most people, the cause of an oligodendroglioma is not known. Like other cancers, it arises from changes in the genes that control how cells grow, but these changes usually develop in the tumor itself rather than being inherited. Two factors have been linked to a higher chance of developing one: earlier radiation exposure to the head and certain inherited gene changes that run in families. Both are uncommon explanations, and most people diagnosed have neither. Oligodendrogliomas can occur at any age but are most common between about 35 and 44, are somewhat more common in men and are rare in children. Nothing a person did or failed to do is known to cause them.
Evaluation usually starts after a seizure or other neurological symptom prompts brain imaging. An MRI (magnetic resonance imaging) scan typically shows a single tumor with fairly well-defined borders and some swelling around it. If the tumor brightens after contrast dye is injected, that is more often seen with grade 3 tumors, but imaging alone cannot confirm the diagnosis. A definite diagnosis requires tumor tissue, obtained during surgery to remove the tumor or, when that is not possible, by biopsy. A neuropathologist, a doctor who specializes in brain tissue, examines the cells and runs genetic tests. Under current definitions, a tumor is an oligodendroglioma only when it has both a mutation in an isocitrate dehydrogenase (IDH) gene and a 1p/19q codeletion, meaning parts of chromosomes 1 and 19 are missing from the tumor cells. These results matter beyond the label: they set the grade, shape the outlook and determine which treatments, including newer targeted medicines, are options.
Surgery is usually the first step when it can be done safely. It provides tissue for diagnosis and aims to remove as much tumor as possible without causing new problems with movement, speech or thinking. Because these tumors spread into nearby brain, some tumor usually remains, and what comes next depends on the grade, how much was removed, age, symptoms and the person's priorities. For adults who need further treatment, the main standard is radiation therapy followed by chemotherapy, according to guidelines from the American Society of Clinical Oncology and the Society for Neuro-Oncology. The chemotherapy most strongly supported is a combination called PCV (procarbazine, lomustine and vincristine). Temozolomide, a chemotherapy taken as capsules, is a reasonable alternative for people unlikely to tolerate PCV, although the evidence for using it first is less strong. Radiation and chemotherapy can both cause side effects, which is part of why their timing is weighed carefully for slow-growing tumors. For some grade 2 tumors, the care team may recommend close monitoring with regular MRI scans instead of treating right away. Another option for grade 2 tumors is vorasidenib (Voranigo), a daily pill approved in 2024 that blocks the abnormal IDH enzyme. It is approved for use after surgery in people 12 and older whose tumor carries a qualifying IDH mutation, and it was studied in, and is mainly used for, people who have not yet needed radiation or chemotherapy. In its main trial, during the follow-up period, the tumor grew in 28 percent of people taking vorasidenib compared with 54 percent taking a placebo, and the need for the next treatment was delayed. It does not replace radiation or chemotherapy when those are needed, and it requires regular liver blood tests because it can cause liver injury. It can also harm a developing pregnancy and can make hormonal birth control less reliable, so people who could become pregnant need a nonhormonal method while taking it, and men taking it whose partners could become pregnant need to use contraception too. Supportive care runs alongside all of this: anti-seizure medicines to control seizures, and sometimes steroid medicines to reduce swelling around the tumor. Clinical trials are an option at many stages.
Oligodendroglioma is usually a long-term condition rather than a single episode of treatment. It is often slow growing, and many people live for years after diagnosis. In adults, about 8 in 10 people are alive five years after diagnosis once deaths from unrelated causes are accounted for, but individual outlook varies widely with grade, age, general health, how much tumor was removed and how the tumor responds to treatment. A care team can explain what the specific pathology and genetic results mean. Even after successful treatment, these tumors can return, so follow-up MRI scans continue long after treatment ends. Seizures may need ongoing medication, and they can affect practical matters such as driving and some kinds of work. Changes in memory, thinking or physical function can come from the tumor or its treatment, and rehabilitation, neuropsychological support and adjustments at work or school can help. Many people find it useful to be treated at, or consult with, a center experienced in brain tumors.
See a doctor promptly for headaches, weakness, numbness, or changes in memory, thinking, speech or balance that are new and persist or keep getting worse. If you already have an oligodendroglioma, contact your care team soon about new or worsening symptoms, seizures that become more frequent or change in pattern, or side effects of treatment that are hard to manage. Call 911 for a seizure in someone who has never had one before, a seizure lasting longer than 5 minutes, seizures that follow one another without the person waking up in between, or if the person does not wake up or return to normal afterward.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Oligodendroglioma is like, what's helped you, or ask the community a question.